Picture of Bicycle Therapeutics logo

BCYC — Bicycle Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapFalling Star

Momentum

Relative Strength (%)
1m-23.38%
3m-59.82%
6m-63.54%
1yr-40.43%
Volume Change (%)
10d/3m+15.24%
Price vs... (%)
52w High-72.1%
50d MA-42.28%
200d MA-60.33%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-18.15%
Return on Equity-33.11%
Operating Margin-559.88%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for BCYC

Will Bicycle Therapeutics's price keep soaring? background image

Will Bicycle Therapeutics's price keep soaring?

Studies by leading experts into the power of price momentum show that stocks with the strongest price trends tend to keep up the pace for anywhere up to one year. A big part of the reason for this is down to investor psychology.  With...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Bicycle Therapeutics EPS forecast chart

Profile Summary

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company that is developing a class of medicines for diseases. The Company is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.

Directors

    Last Annual
    December 31st, 2021
    Last Interim
    March 31st, 2022
    Incorporated
    October 27th, 2017
    Public Since
    May 23rd, 2019
    No. of Shareholders
    63
    No. of Employees
    119
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Select Market
    Shares in Issue
    29,648,534

    BCYC Share Price Performance

    Upcoming Events for BCYC

    Bicycle Therapeutics PLC Annual Shareholders Meeting

    Q2 2022 Bicycle Therapeutics PLC Earnings Release

    Q3 2022 Bicycle Therapeutics PLC Earnings Release

    Similar to BCYC

    Picture of 2Seventy Bio logo

    2Seventy Bio

    us flag iconNASDAQ Global Select Market

    Picture of 4D Molecular Therapeutics logo

    4D Molecular Therapeutics

    us flag iconNASDAQ Global Select Market

    Picture of AbCellera Biologics logo

    AbCellera Biologics

    us flag iconNASDAQ Global Select Market

    Picture of AbSci logo

    AbSci

    us flag iconNASDAQ Global Select Market

    Picture of ACADIA Pharmaceuticals logo

    ACADIA Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    FAQ

    Or unlock with your email

    Or unlock with your email